Matrix metalloproteinases and their tissue inhibitors after selective laser trabeculoplasty in pseudoexfoliative secondary glaucoma

BMC Ophthalmology

Volumn 8, Issue , 2008, Pages

  Cellini, Mauro ^a   Leonetti, Pietro ^a   Strobbe, Ernesto ^a   Campos, Emilio C ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DORZOLAMIDE; EYE DROPS; GELATINASE A; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CATARACT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE EXAMINATION; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LASER SURGERY; MALE; OCULOPLETHYSMOGRAPHY; PHACOEMULSIFICATION; PROTEIN BLOOD LEVEL; PSEUDOEXFOLIATION; SELECTIVE LASER TRABECULOPLASTY; STATISTICAL SIGNIFICANCE; TRABECULECTOMY; TRABECULOPLASTY; TREATMENT FAILURE; TREATMENT OUTCOME; VISUAL ACUITY; EXFOLIATION SYNDROME; LOW LEVEL LASER THERAPY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; POSTOPERATIVE PERIOD;

AGED; AQUEOUS HUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXFOLIATION SYNDROME; FEMALE; HUMANS; INTRAOCULAR PRESSURE; LASER THERAPY; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; POSTOPERATIVE PERIOD; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRABECULECTOMY;

EID: 55149088877     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-8-20     Document Type: Article

References (39)

1. Laser trabeculoplasty. RN Weinreb S Tsai, The glaucomas: glaucoma therapy St Louis: Mosby-Year Book, Ritch R, Shields MB, Krupin T, 2 1996 1575 90
2. Selective laser trabeculoplasty as primary treatment for open-angle glaucoma. S Melamed GJB Simon H Levkovitch-Verbin, Arch Ophthalmol 2003 121 957 960 10.1001/archopht.121.7.957 12860797
3. Argon laser therapy for open angle glaucoma: a pilot study. JB Wise SL Witter, Arch Ophthalmol 1979 97 319 22 575877
4. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and Q-sw laser interactions. MA Latina C Park, Exp Eye Res 1995 60 359 72 10.1016/S0014-4835(05)80093-4 7789416
5. Selective laser trabeculoplasty vs argon laser trabeculoplasty: a prospective randomised clinical trial. KF Damji KC Shah WJ Rock HS Bains WG Hodge, Br J Ophthalmol 1999 83 718 722 10340983
6. A review of argon and selective laser trabeculoplasty as primary treatments of open-angle glaucoma. P Sanfilippo, Clin Exp Optom 1999 82 6 225 229 12482268
7. Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. TR Kramer RJ Noecker, Ophthalmology 2001 108 773 779 10.1016/S0161-6420(00)00660-6 11297496
8. Mediation of laser trabeculoplasty induced matrix metalloproteinase expression by IL-1β and TNFα JM Bradly AM Anderssohn CM Colvis DE Parshley XH Zhu MS Ruddat JR Samples TS Acott, Invest Ophthalmol Vis Sci 2000 41 422 430 10670472
9. Selective laser trabeculoplasty. MA Latina JM DeLeon, Ophthalmol Clin N Am 2005 18 409 419 10.1016/j.ohc.2005.05.005
10. Selective laser trabeculoplasty a new treatment option for open angle glaucoma. MA Latina JA Tumbocon, Curr Opin Ophthalmol 2002 13 94 96 10.1097/00055735-200204000-00007 11880722
11. Selective laser trabeculoplasty (SLT) complicated by intraocular pressure elevation in eyes with heavily pigmented trabecular meshworks. PJ Harasymowycz DG Papamatheakis M Latina M De Leon M Lesk KF Damji, Am J Ophthalmol 2005 139 1110 1113 10.1016/j.ajo.2004.11.038 15953448
12. Laser trabeculoplasty induces stromelysin expression by trabecular juxtacanilicular cells. DE Parshley JM Bradley A Fisk A Hadaegh JR Samples EM Van Buskirk TS Acott, Invest Ophthalmol Vis Sci 1996 37 795 804 8603864
13. Matrix metalloproteinases. A mini-review. H Nagase, Contrib Nephrol 1994 107 85 93 8004978
14. 37 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. EB Springman EL Angleton H Birkedal-Hansen HE Van Wart, Proc Nat Acad Sci USA 1990 87 364 368 2153297 10.1073/pnas.87.1.364
15. Regulation of matrix metalloproteinase activity. G Murphy F Willenbrock T Crabbe M O'Shea R Ward S Atkinson J O'Connell A Docherty, Ann NY Acad Sci 1994 732 31 41 10.1111/j.1749-6632.1994.tb24722.x 7978800
16. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl) mercuric acetate. H Nagase JJ Enghild K Suzuki G Salvesen, Biochemistry 1990 29 5783 5789 10.1021/bi00476a020 2383557
17. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. Y Ogata JJ Enghild H Nagase, J Biol Chem 1992 267 3581 3584 1371271
18. Matrix metalloproteinases: a review. H Birkedal-Hansen WG Moore MK Bodden LJ Windosor B Birkedal-Hansen A De Carlo JA Engler, Crit Rev Oral Biol Med 1993 4 197 250 8435466
19. Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. DT Denhardt B Feng DR Edwards ET Cocuzzi UM Malyankar, Pharmacol Ther 1993 59 329 341 10.1016/0163-7258(93) 90074-N 8309995
20. Tissue inhibitor of metalloproteinases: structure regulation and biological functions. DE Gomez DF Alonso H Yoshiji UP Thorgeirsson, Eur J Cell Biol 1997 74 111 122 9352216
21. Binding of tissue inhibitor of metalloproteinases 2 to two distinct sites on human 72-kDa gelatinase. EW Howard MJ Banda, J Biol Chem 1991 266 17972 17977 1655733
22. Matrix metalloproteinases and their inhibitors in acqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma. U Schlötzer-Schrehardt J Lommatzsch M Kuchle AG Konstas GO Naumann, Invest Ophthalmol Vis Sci 2003 44 1117 1125 10.1167/iovs.02-0365 12601038
23. Matrix metalloproteinases and their tussue inhibitors an aqueous humor of patients with primary open angle glaucoma, exfoliation syndrome and exfoliation glaucoma. M Määttä T Tervahartiala M Harju J Airaksinen H Auto-Harmainen T Sorsa, J Glaucoma 2005 14 64 69 10.1097/01.ijg.0000145812. 39224.0a 15650607
24. Exfoliation Syndrome. R Ritch U Schlötzer-Schrehardt, Survey Ophthalmol 2001 45 265 314 10.1016/S0039-6257(00)00196-X
25. Pseudoexfoliation syndrome: ocular manifestation of a systemic disorder? U Schlötzer-Schrehardt MR Koca GO Naumann H Volkholz, Arch Ophthalmol 1992 110 1752 1756 1463418
26. Pseudoextoliative fibrillopathy in visceral organs of a patient with pseudoexfoliation syndrome. BW Streeten Z-Y Li RN Wallace RC Eagle AA Keshgegian, Arch Ophthalmol 1992 110 1757 1762 1463419
27. Pupillary dilatation in eyes with pseudoexfoliation syndrome. EF Carpel, Am J Ophthalmol 1988 105 692 694 3377050
28. Pupil dilatation in the pseudoexfoliation syndrome. NJ Watson S Winder FD Green, Eye 1995 9 341 343 7556744
29. Pseudoexfoliation of the lens capsule, II. Development of the exfoliation syndrome. E Hansen OJ Sellevold, Acta Ophthalmol (Copenh) 1969 47 1 161 173 5819822
30. Clinical signs of the pseudoexfoliation syndrome. AM Prince R Ritch, Ophthalmology 1986 93 803 807 3737125
31. Generalized peripheral iris transluminance in the pseudoexfoliation syndrome. LP Repo ME Teràsvirta EJ Tuovinen, Ophthalmology 1990 97 1027 1029 2402412
32. A histopathologic study of iris changes in pseudoexfoliation syndrome. A Asano U Schlötzer-Schrehardt GO Naumann, Ophthalmology 1995 102 1279 1290 9097764
33. Morphology of iris vasculopathy in exfoliation glaucoma. AGP Konstas GE Marshall SA Cameron WR Lee, Acta Ophthalmol (Copenh) 1993 71 6 751 759 8154248
34. Fluorescein angiography and fluorophotometry of the iris in pseudoexfoliation of the lens capsule. AMV Brooks WE Gillies, Br J Ophthalmol 1983 67 249 254 6187357 10.1136/bjo.67.4.249
35. Vascular changes in pseudoexfoliation of the lens capsule and capsular glaucoma: a fluorescein angiographic and electron microscopic study. A Vannas, Graefes Arch Clin Exp Ophthalmol 1972 184 248 253 10.1007/BF00413298
36. Unilateral or asymmetric pseudoexfoliation syndrome? T Hammer U Schlötzer-Schrehardt GO Naumann, Arch Ophthalmol 2001 119 1023 1031 11448324
37. The fellow eye in unilateral hypertensive pseudoexfoliation. PE Pohjanpelto, Am J Ophthalmol 1973 75 216 220 4697178
38. Aqueous dynamics in exfoliation syndrome. NZ Gharagozloo RH Baker RF Brubaker, Am J Ophthalmol 1992 114 473 478 1415459
39. Pathogenic A beta induces the expression and activation of matrix metalloproteinase-2 in human cerebrovascolar smooth muscle cells. S Jung W Zhang WE Van Nostrand, J Neurochem 2003 85 1208 1215 10.1046/j.1471-4159.2003.01745.x 12753080